FDA expands faricimab label to include treatment of macular edema secondary to retinal vein occlusion beyond 6 months

The US Food and Drug Administration (FDA) has allowed a change to the label for faricimab-svoa (Vabysmo; Genentech) to include treatment for macular edema caused by retinal vein occlusion (RVO) for more than 6 months. The decision extends the duration of use reflected in the prescribing information and may reduce the need for treatment switches in patients demonstrating sustained response.

Macular edema due to RVO remains a common cause of vision loss, affecting more than 1 million individuals in the United States.¹ Chronic disease activity often necessitates prolonged intravitreal therapy, with anti–vascular endothelial growth factor (VEGF) agents forming the cornerstone of treatment. The updated labeling for faricimab reflects longer-term use aligned with clinical trial data and real-world treatment patterns.

Regulatory and trial overview

Faricimab is a bispecific monoclonal antibody targeting both angiopoietin-2 (Ang-2) and VEGF-A. Its dual mechanism distinguishes it from earlier anti-VEGF monotherapies such as ranibizumab and aflibercept. The FDA initially approved faricimab for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in 2022, followed by approval for macular edema secondary to RVO in 2023.²

The current label update is based on phase 3 clinical trials in RVO, such as the BALATON (branch RVO) and COMINO (central RVO) studies. These randomized, double-masked trials evaluated faricimab against aflibercept in treatment-naïve patients with macular edema due to RVO. At 24 weeks, faricimab demonstrated noninferiority to aflibercept in best-corrected visual acuity (BCVA) gains, with comparable reductions in central subfield thickness.³

While the primary endpoints were assessed at 24 weeks, extension phases of these trials and additional analyses have examined durability and safety beyond 6 months. The updated label reflects these longer-term data, though detailed outcomes from extended follow-up have been less extensively published in peer-reviewed literature at the time of writing.

Clinical context

Retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy and is associated with significant visual morbidity.¹ Macular edema is the primary driver of vision loss in RVO, and timely initiation of therapy is critical for optimal outcomes.

Anti-VEGF therapy has been the standard of care, with agents such as aflibercept and ranibizumab demonstrating substantial visual gains in pivotal trials.⁴⁻⁵ However, many patients require frequent injections to maintain disease control, contributing to treatment burden and potential adherence challenges.

The introduction of faricimab offers an alternative approach by targeting both VEGF-A and Ang-2, a pathway implicated in vascular instability and inflammation. Preclinical and clinical data suggest that dual inhibition may improve vascular stability and potentially extend dosing intervals in some patients.⁶

Drug background and mechanism

Faricimab is the first bispecific antibody approved for intraocular use. By simultaneously inhibiting VEGF-A and Ang-2, it aims to reduce vascular permeability, inflammation, and neovascularization. Ang-2 is thought to destabilize endothelial junctions and promote sensitivity to VEGF signaling, making it a complementary therapeutic target.

In prior phase 3 trials in DME (YOSEMITE and RHINE) and nAMD (TENAYA and LUCERNE), faricimab demonstrated efficacy comparable to aflibercept, with a proportion of patients achieving extended dosing intervals up to 16 weeks.⁷⁻⁸ These findings contributed to its adoption in clinical practice as a potential option for reducing injection frequency.

Interpretation and clinical implications

The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated evidence supporting its continued efficacy and safety over longer treatment periods. For clinicians, this may reduce uncertainty around prolonged use and limit the need for switching therapies in stable responders.

However, the clinical impact of this update may be incremental rather than practice-changing. Retina specialists have already been using anti-VEGF therapies chronically in RVO, often guided by disease activity rather than strict label duration. The updated labeling may instead serve to formalize existing practice patterns.

Limitations and next steps

Peer-reviewed data on outcomes beyond 6 months in RVO populations treated with faricimab are still limited. While extension studies and real-world evidence are emerging, longer-term comparative effectiveness and safety data will be important to clarify durability and optimal dosing strategies.

It is still not clear if dual Ang-2/VEGF inhibition offers any real benefits over VEGF monotherapy in RVO beyond noninferiority. Head-to-head studies powered for durability or treatment burden endpoints may help address this question.

Ongoing surveillance and postmarketing data will be critical to understanding long-term safety, particularly with respect to intraocular inflammation and rare adverse events associated with intravitreal biologics.

References

1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies. Ophthalmology. 2010;117(2):313-319.
   https://doi.org/10.1016/j.ophtha.2009.07.017

2. US Food and Drug Administration. FDA approves faricimab-svoa for retinal vascular diseases.
   https://www.fda.gov/drugs

3. ClinicalTrials.gov. A study to evaluate the efficacy and safety of faricimab in participants with macular edema secondary to retinal vein occlusion (BALATON).
   https://clinicaltrials.gov/ct2/show/NCT04740905

4. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: CRUISE study. Ophthalmology. 2010;117(6):1124-1133.
   https://doi.org/10.1016/j.ophtha.2010.02.022

5. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept for macular edema following central retinal vein occlusion: GALILEO study. Ophthalmology. 2014;121(1):202-208.
   https://doi.org/10.1016/j.ophtha.2013.08.012

6. Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of Ang-2 and VEGF-A with faricimab in retinal disease. Ophthalmology. 2020;127(5):642-653.
   https://doi.org/10.1016/j.ophtha.2019.11.025

7. Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of faricimab in diabetic macular edema (YOSEMITE and RHINE). Lancet. 2022;399(10326):741-755.
   https://doi.org/10.1016/S0140-6736(22)00018-6

8. Dugel PU, Singh RP, Koh A, et al. Faricimab in neovascular age-related macular degeneration (TENAYA and LUCERNE). Lancet. 2022;399(10326):729-740.
   https://doi.org/10.1016/S0140-6736(22)00010-1